Insulin pump manufacturer Insulet has announced their new Omnipod 5 device has at last received regulatory approval from the American Food and Drug Administration (FDA) after months of delay caused by the covid pandemic. The approval means that the Omnipod 5 will be used with Dexcom’s G6 continuous glucose monitor providing their first closed-loop insulin delivery system via a tubeless pump. The system detects changes in blood glucose levels and automatically adjusts patients’ insulin doses. The device provides three days of continuous insulin dosing in a disposable, wearable patch pump. Wall Street investors have labelled Omnipod 5 as the year’s most exciting new medical device as the market for wearable devices such as insulin pumps and continuous glucose monitors takes off.